Search

Supplementary Table 3. Risk of death from breast cancer between diagnostic periods, for each molecular subtype 5 and 15 years after diagnosis (Cox regression analysis).

Supplementary Figure 2. Subtype-specific incidence rates according to age and year of birth. Blue lines: Women born before 1929. Red lines: Women born in 1929 or later. Dotted lines (red and blue) represent incidence rates of subtyped cases. Solid lines (red and blue) represent average incidence rates from 50 imputed datasets with corresponding 95% confidence intervals (CIs).

Supplementary Figure 3. Cumulative incidence of death from breast cancer according to breast cancer subtypes. A: Women diagnosed before 1995 (Gray's test: p=0.0002). B: Women diagnosed in 1995 or later (Gray's test: p

Supplementary Table 1. Characteristics of the study population used in estimations of breast cancer incidence.

Supplementary Table 2. Incidence rates and incidence rate ratios of breast cancer according to hormone and HER2 receptor status, age at diagnosis and year of birth. Observed and imputed estimates.

Supplementary Figure legends.

Supplementary Table 5. Risk of death from breast cancer between diagnostic periods, for each breast cancer subtype 5 and 15 years after diagnosis (Cox regression analysis).

Supplementary Figure legends.

Background: Secular trends in incidence and prognosis of molecular breast cancer subtypes are poorly described. We studied long-term trends in a population of Norwegian women born 1886–1977.Methods: A total of 52,949 women were followed for breast cancer incidence, and 1,423 tumors were reclassified into molecular subtypes using IHC and in situ hybridization. We compared incidence rates among women born 1886–1928 and 1929–1977, estimated age-specific incidence rate ratios (IRR), and performed multiple imputations to account for unknown subtype. Prognosis was compared for women diagnosed before 1995 and in 1995 or later, estimating cumulative risk of death and HRs.Results: Between 50 and 69 years of age, incidence rates of Luminal A and Luminal B (HER2−) were higher among women born in 1929 or later, compared with before 1929 [IRRs 50–54 years; after imputations: 3.5; 95% confidence interval (CI), 1.8–6.9 and 2.5; 95% CI, 1.2–5.2, respectively], with no clear differences for other subtypes. Rates of death were lower in women diagnosed in 1995 or later, compared to before 1995, for Luminal A (HR 0.4; 95% CI, 0.3–0.5), Luminal B (HER2−; HR 0.5; 95% CI, 0.3–0.7), and Basal phenotype (HR 0.4; 95% CI, 0.2–0.9).Conclusions: We found a strong secular incidence increase restricted to Luminal A and Luminal B (HER2−) subtypes, combined with a markedly improved prognosis for these subtypes and for the Basal phenotype.Impact: This study documents a clear secular increase in incidence and a concomitant improved prognosis for specific molecular breast cancer subtypes. Cancer Epidemiol Biomarkers Prev; 25(12); 1625–34. ©2016 AACR.